NDA 217186 · Impax
Crexont
Carbidopa, Levodopa · Oral · Aromatic Amino Acid
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 7, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
262
53 Phase 3, 16 recruiting
FAERS reports
5,848
3,390 serious, 622 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2026.
CREXONT is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. ( 1 )
Mechanism: Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats symptoms of Parkinson's disease.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- CREXONT · CARBIDOPA 70MG; LEVODOPA 280MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- CREXONT · CARBIDOPA 35MG; LEVODOPA 140MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- CREXONT · CARBIDOPA 87.5MG; LEVODOPA 350MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
- CREXONT · CARBIDOPA 52.5MG; LEVODOPA 210MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbidopa" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00099268 · 747 participants · Start Sep 2004 · Primary completion Nov 2008
Drug: Carbidopa/levodopa/entacapone; Immediate release carbidopa/levodopa · For: Parkinson's Disease
Sites: Birmingham, Alabama; Scottsdale, Arizona; La Jolla, California · 73 sites in all
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsPivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT03670953 · 630 participants · Start Nov 6, 2018 · Primary completion Jun 15, 2021
Drug: IR CD-LD; IPX203 ER CD-LD · For: Parkinson's Disease (Disorder)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Loma Linda, California · 108 sites in all
- An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseasePivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT01096186 · 617 participants · Start Mar 2010 · Primary completion Oct 2011
Drug: IPX066 95 mg; IPX066 145 mg and 2 more · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 81 sites in all
- Enhancement of Stroke Rehabilitation With LevodopaPivotal-lookingActive, not recruiting
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT03735901 · 610 participants · Start Jun 14, 2019 · Primary completion Aug 27, 2024
Drug: IMP Levodopa 100mg/Carbidopa 25mg; Matching placebo · For: Acute Stroke; Stroke Rehabilitation
Sites: Aarau, Switzerland; Bad Zurzach, Switzerland; Baden, Switzerland · 24 sites in all
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01568073 · 600 participants · Start Mar 2011 · Primary completion Nov 2013
Drug: BIA 9-1067; Entacapone and 4 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
- A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on LevodopaPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT00199420 · 580 participants · Start Jul 2004 · Primary completion Nov 2005
Drug: Istradefylline (KW-6002) · For: Parkinson's Disease
Sites: Princeton, New Jersey · 2 sites in all
- A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00134966 · 493 participants · Start Aug 2005 · Primary completion Sep 2007
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) · For: Parkinson's Disease
Sites: Phoenix, Arizona; La Jolla, California; Reseda, California · 60 sites in all
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).Pivotal-lookingCompleted
Impax Laboratories, LLCIndustry
NCT00974974 · 471 participants · Start Sep 2009 · Primary completion Jan 2011
Drug: IPX066; IR CD-LD · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 73 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective659
- fall514
- hallucination512
- dyskinesia443
- tremor386
- nausea317
- dizziness306
- death296
- fatigue281
- gait disturbance275
- cough270
- parkinson^s disease263
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 96 |
| 2005 | 92 |
| 2006 | 85 |
| 2007 | 107 |
| 2008 | 224 |
| 2009 | 122 |
| 2010 | 150 |
| 2011 | 141 |
| 2012 | 134 |
| 2013 | 31 |
| 2014 | 67 |
| 2015 | 121 |
| 2016 | 192 |
| 2017 | 408 |
| 2018 | 380 |
| 2019 | 293 |
| 2020 | 418 |
| 2021 | 299 |
| 2022 | 272 |
| 2023 | 194 |
| 2024 | 310 |
| 2025 | 1,044 |
| 2026 | 668 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Crexont (Carbidopa/Levodopa)
2024 spending
$2.5M
Beneficiaries
1,825
2,918 claims
Per beneficiary
$1,365
$4.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,491,021 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ, Aldred J, Budur K, et al. · Lancet Neurol 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA · Neurology 2004 · Clinical Trial
- Levodopa and the progression of Parkinson's disease.
Fahn S, Oakes D, Shoulson I, et al. · N Engl J Med 2004 · Clinical Trial, Multicenter Study
- Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial.
Engelter ST, Kaufmann JE, Zietz A, et al. · JAMA 2025 · Clinical Trial, Phase III, Multicenter Study
- Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson's Disease.
Lewis MM, Van Scoy LJ, De Jesus S, et al. · Biomolecules 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials.
Yan R, Zheng X, Yin Y, et al. · Mov Disord 2025 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Impax
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.